Quench Medical
Quench Medical is dedicated to advancing respiratory drug delivery for treating lung diseases, with a focus on inhalation therapies that improve efficacy and safety. The company aims to develop next-generation treatments for lung conditions, including lung cancer and ARDS, by delivering drugs directly to the lungs via inhalation, thereby overcoming challenges associated with traditional delivery methods.
Industries
Nr. of Employees
small (1-50)
Products
Inhaled dry powder therapy for lung cancer (preclinical)
A dry powder inhalation therapy intended to deliver chemotherapeutic agents directly to lung tumors; demonstrated preclinical efficacy in lung cancer models at reduced systemic doses.
Inhaled stem-cell derived biologic candidate for ARDS (development project)
Grant-funded program to develop an inhaled biologic derived from stem cells aimed at treating acute respiratory distress syndrome.
Inhaled psychoplastogenic therapeutic for opioid use disorder (development project)
SBIR-funded program to develop an inhaled psychoplastogenic therapeutic intended to improve treatment of opioid use disorder.
Inhaled therapy targeting small airways for asthma (development project)
Proprietary inhaled therapy aimed at targeting the small airways for asthma treatment, supported by grant funding.
Inhaled therapy for pneumothorax (collaborative project)
SBIR-funded collaborative program with a clinical research partner to develop an inhaled treatment for pneumothorax.
Inhaled dry powder therapy for lung cancer (preclinical)
A dry powder inhalation therapy intended to deliver chemotherapeutic agents directly to lung tumors; demonstrated preclinical efficacy in lung cancer models at reduced systemic doses.
Inhaled stem-cell derived biologic candidate for ARDS (development project)
Grant-funded program to develop an inhaled biologic derived from stem cells aimed at treating acute respiratory distress syndrome.
Inhaled psychoplastogenic therapeutic for opioid use disorder (development project)
SBIR-funded program to develop an inhaled psychoplastogenic therapeutic intended to improve treatment of opioid use disorder.
Inhaled therapy targeting small airways for asthma (development project)
Proprietary inhaled therapy aimed at targeting the small airways for asthma treatment, supported by grant funding.
Inhaled therapy for pneumothorax (collaborative project)
SBIR-funded collaborative program with a clinical research partner to develop an inhaled treatment for pneumothorax.
Services
End-to-end development of inhaled therapeutic candidates through formulation, device integration, and preclinical efficacy testing, performed internally and via external collaborations.
Management and execution of SBIR- and grant-funded programs to advance inhaled candidates through preclinical stages.
End-to-end development of inhaled therapeutic candidates through formulation, device integration, and preclinical efficacy testing, performed internally and via external collaborations.
Management and execution of SBIR- and grant-funded programs to advance inhaled candidates through preclinical stages.
Expertise Areas
- Pulmonary drug delivery
- Dry powder formulation development
- Device–formulation co-development for DPIs
- Preclinical oncology and respiratory models
Key Technologies
- Dry powder inhalation
- Dry powder aerosol formulation
- Excipient-enhanced aerosol growth
- Dry powder inhaler (DPI) design
News & Updates
A grant to develop an inhaled biologic therapy for ARDS, a life-threatening complication of sepsis, pneumonia, and COVID-19.
A Phase I SBIR grant to develop an inhaled therapy for treating persons with opioid use disorder.
The company becomes a member of the Medical Alley Association, enhancing its network and resources in healthcare innovation.
The company was featured in an article discussing its inhaled lung cancer treatment.
The company's progress was presented at the gBETA Medtech accelerator event.
An article published by Dr. Beverlin and colleagues discussing delivery options for lung disease treatments.
A grant to develop an inhaled biologic therapy for ARDS, a life-threatening complication of sepsis, pneumonia, and COVID-19.
A Phase I SBIR grant to develop an inhaled therapy for treating persons with opioid use disorder.
The company becomes a member of the Medical Alley Association, enhancing its network and resources in healthcare innovation.
The company was featured in an article discussing its inhaled lung cancer treatment.
The company's progress was presented at the gBETA Medtech accelerator event.
An article published by Dr. Beverlin and colleagues discussing delivery options for lung disease treatments.